DIAGNOS Inc. (TSXV: ADK)
Canada
· Delayed Price · Currency is CAD | Market Cap | 29.50M |
| Revenue (ttm) | 153.49K |
| Net Income (ttm) | -3.35M |
| Shares Out | 95.15M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,500 |
| Open | 0.320 |
| Previous Close | 0.320 |
| Day's Range | 0.310 - 0.320 |
| 52-Week Range | 0.230 - 0.430 |
| Beta | -0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 28, 2024 |
About DIAGNOS
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was found... [Read more]
Financial Performance
In 2023, DIAGNOS's revenue was 170,158, a decrease of -64.97% compared to the previous year's 485,749. Losses were -3.12 million, 25.8% more than in 2022.
Financial StatementsNews
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Oct. 25, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces the Engagement of Market Maker Consultant
BROSSARD, Quebec, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces Grant of Stock Options
BROSSARD, Quebec, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Announces Voting Results of Meeting of Shareholders
BROSSARD, Quebec, Sept. 26, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Announces Variation in One Insider Ownership
BROSSARD, Quebec, Sept. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that as a res...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Quebec, Sept. 20, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
BROSSARD, Quebec, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the us...
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
BROSSARD, Quebec, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the us...
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
BROSSARD, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its F...
DIAGNOS Announces Closing of First Tranche of Private Placement
BROSSARD, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the u...
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical...
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critic...
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (ADK TSX: OTCQB: DGNOF), based in Montreal, Canada, focused on Artificial Intelligence for the medical market, today announced that André Lare...
DIAGNOS Announces Grant of Stock Options
BROSSARD, Quebec, April 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
BROSSARD, Quebec, April 02, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the...
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
BROSSARD, Quebec, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
Diagnos Announces Variation in One Insider Ownership of Common Shares
BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that on Februa...
DIAGNOS recognized as a Top TSX Venture Exchange Company
BROSSARD, Quebec, Feb. 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its ...
DIAGNOS Appoints New Chief Operating Officer
BROSSARD, Quebec, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the ...
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
BROSSARD, Quebec, Dec. 11, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its ...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Québec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health...
DIAGNOS AI Retina Analysis is being deployed across Canada's Largest Specialist Care Provider in Diabetes & Endocrinology
BROSSARD, Quebec, Oct. 05, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health...
DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants
BROSSARD, Quebec, May 18, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health ...
DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”
BROSSARD, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through t...